Brickell Tangible Assets Book Value per Share Trend from 2010 to 2022

BBI -  USA Stock  

USD 0.12  0.01  7.69%

Brickell Biotech Tangible Assets Book Value per Share are decreasing over the last several years with slightly volatile swings. Tangible Assets Book Value per Share are estimated to finish at 0.38 this year. During the period from 2010 to 2022 Brickell Biotech Tangible Assets Book Value per Share regressed destribution of quarterly values had coefficient of variationof 79.34 and r-value of (0.95). Brickell Biotech Interest Expense is most likely to decrease significantly in the upcoming years. The last year's value of Interest Expense was reported at 62,100. The current Revenues is estimated to increase to about 414.6 K, while Consolidated Income is projected to decrease to (40.5 M).
  
Refresh
Check Brickell Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brickell main balance sheet or income statement drivers, such as Cost of Revenue of 7.3 M, Gross Profit of 414.6 K or Interest Expense of 63.7 K, as well as many exotic indicators such as Asset Turnover of 0.0133, Book Value per Share of 0.32 or Current Ratio of 6.47. Brickell financial statements analysis is a perfect complement when working with Brickell Biotech Valuation or Volatility modules. It can also supplement various Brickell Biotech Technical models. Continue to the analysis of Brickell Biotech Correlation against competitors.

Brickell Biotech Quarterly Tangible Assets Book Value per Share

0.174

Share

Brickell Tangible Assets Book Value per Share Breakdown

Showing smoothed Tangible Assets Book Value per Share of Brickell Biotech with missing and latest data points interpolated. Measures the ratio between Tangible Asset Value and [SharesWA] as adjusted by [ShareFactor].Brickell Biotech's Tangible Assets Book Value per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brickell Biotech's overall financial position and show how it may be relating to other accounts over time.
Tangible Assets Book Value per Share10 Years Trend
Decreasing
Slightly volatile
 Tangible Assets Book Value per Share 
Share
      Timeline 

Brickell Tangible Assets Book Value per Share Regression Statistics

Arithmetic Mean 33.80
Geometric Mean 13.84
Coefficient Of Variation 79.34
Mean Deviation 22.57
Median 37.09
Standard Deviation 26.81
Sample Variance 718.93
Range 75.94
R-Value(0.95)
Mean Square Error 74.54
R-Squared 0.90
Significance 0.00000059
Slope(6.55)
Total Sum of Squares 8,627

Brickell Tangible Assets Book Value per Share History

2012 76.31
2013 51.9
2014 44.4
2015 37.09
2016 35.96
2017 43.34
2018 14.15
2019 6.0
2020 1.37
2021 0.37
2022 0.38

About Brickell Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brickell Biotech income statement, its balance sheet, and the statement of cash flows. Brickell Biotech investors use historical funamental indicators, such as Brickell Biotech's Tangible Assets Book Value per Share, to determine how well the company is positioned to perform in the future. Although Brickell Biotech investors may use each financial statement separately, they are all related. The changes in Brickell Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brickell Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brickell Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brickell Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Tangible Assets Book Value per Share 0.37  0.38 
Tangible Asset Value29.7 M36.7 M
Average Assets30.5 M39.2 M
Enterprise ValueM5.1 M
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brickell Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Shere Portfolio Now

   

Shere Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Brickell Biotech Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Brickell Biotech Correlation against competitors. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
14.5 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.